MyFinsight

HomeCompareAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Privacy Policy
  • Contact

Follow Us

  • Thread
  • X.com
  • Instagram

© 2026 MyFinsight. All rights reserved.

Recent SEC Filings
10/2NIKE, Inc.(NKE)10/2DARDEN RESTAURANTS INC(DRI)9/30CONAGRA BRANDS INC.(CAG)9/29Carnival Corp Ltd.(CCL)9/29URANIUM ENERGY CORP(UEC)9/29COPART INC(CPRT)9/24BLACKBERRY Ltd(BB)9/24PAYCHEX INC(PAYX)9/23GENERAL MILLS INC(GIS)9/22ADOBE INC.(ADBE)9/18KROGER CO(KR)10/2NIKE, Inc.(NKE)10/2DARDEN RESTAURANTS INC(DRI)9/30CONAGRA BRANDS INC.(CAG)9/29Carnival Corp Ltd.(CCL)9/29URANIUM ENERGY CORP(UEC)9/29COPART INC(CPRT)9/24BLACKBERRY Ltd(BB)9/24PAYCHEX INC(PAYX)9/23GENERAL MILLS INC(GIS)9/22ADOBE INC.(ADBE)9/18KROGER CO(KR)
||
||

Income Overview

Net Income
-$32,711K
EPS
-$0.47
Unit: Thousand (K) dollars
Income Statement
2026-07-31
2026-04-30
2026-01-31
2025-10-31
Research and development
20,090
22,195
22,255
26,755*
General and administrative
13,924
9,773
8,930
6,569*
Total operating expenses
34,014
31,968
31,185
33,324
Loss from operations
-34,014
-31,968
-31,185
-33,324*
Interest income
2,401
2,663
2,740
2,727*
Interest expense
843
745
732
720*
Loss on extinguishment of debt
-
-
-488
0*
Other expenses, net
-45
-177
-87
271*
Total other income, net
1,513
1,741
1,433
2,278*
Net loss before income taxes
-32,501
-30,227
-29,752
-31,046*
Provision for income taxes
0
0
0
-717*
Net loss
-32,501
-30,227
-29,752
-30,329*
Unrealized loss (gain) on available-for-sale investments
-210
-299
46
1,251*
Total comprehensive loss
-32,711
-30,526
-29,706
-29,078
Basic EPS
-0.47
-0.43
0.44
-0.569
Diluted EPS
-0.47
-0.43
0.44
-0.569
Basic Average Shares
69,734,610
69,724,761
67,263,234
51,141,247
Diluted Average Shares
69,734,610
69,724,761
67,263,234
51,141,247
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

ENGNW Income Statement Sankey DiagramSankey diagram visualizing ENGNW income statement for the periodTotal comprehensiveloss-$32,711K (-11.91%↓ Y/Y)Net loss-$32,501K (-12.11%↓ Y/Y)Unrealized loss (gain) onavailable-for-sale investments-$210K (12.50%↑ Y/Y)Interest income$2,401K (7.52%↑ Y/Y)Net loss beforeincome taxes-$32,501K (-13.04%↓ Y/Y)Total other income,net$1,513K (26.61%↑ Y/Y)Interest expense$843K (11.21%↑ Y/Y)Other expenses, net-$45K (83.93%↑ Y/Y)Loss from operations-$34,014K (-13.58%↓ Y/Y)Total operatingexpenses$34,014K (13.58%↑ Y/Y)Research and development$20,090K (-11.01%↓ Y/Y)General andadministrative$13,924K (88.88%↑ Y/Y)

enGene Therapeutics Inc. (ENGNW)

enGene Therapeutics Inc. (ENGNW)